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Metastasis development represents an important threat for melanoma
patients, even when diagnosed at early stages and upon removal of the pri-
mary tumor. In this scenario, determination of prognostic biomarkers would
be of great interest. Serum contains information about the general status of
the organism and therefore represents a valuable source for biomarkers. Thus,
we aimed to define serological biomarkers that could be used along with clini-
cal and histopathological features of the disease to predict metastatic events
on the early-stage population of patients. We previously demonstrated that in
stage II melanoma patients, serum levels of dermcidin (DCD) were associated
with metastatic progression. Based on the relevance of the immune response
on the cancer progression and the recent association of DCD with local and
systemic immune response against cancer cells, serum DCD was analyzed in a
new cohort of patients along with interleukin 4 (IL-4), IL-6, IL-10, IL-17A,
interferon c (IFN-c), transforming growth factor-b (TGF- b), and granulo-
cyte–macrophage colony-stimulating factor (GM-CSF). We initially recruited
448 melanoma patients, 323 of whom were diagnosed as stages I-II according
to AJCC. Levels of selected cytokines were determined by ELISA and Lumi-
nex, and obtained data were analyzed employing machine learning and
Kaplan–Meier techniques to define an algorithm capable of accurately classi-
fying early-stage melanoma patients with a high and low risk of developing
metastasis. The results show that in early-stage melanoma patients, serum
levels of the cytokines IL-4, GM-CSF, and DCD together with the Breslow
thickness are those that best predict melanoma metastasis. Moreover, result-
ing algorithm represents a new tool to discriminate subjects with good prog-
nosis from those with high risk for a future metastasis.
Abbreviations
DCD, dermcidin; GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN, interferon; IL, Interleukin; TGF, transforming growth
factor; Th, T helper.
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1. Introduction
Early and accurate classification of patients is the
cornerstone of precision medicine, intimately linked
to the optimal management of cancer. This is espe-
cially relevant for melanoma, the most deadly type of
skin cancer due to its high metastatic capacity and
the limited, although promising, therapeutic tools
available to combat the advanced disease (Eggermont
et al., 2018). Current data indicate an overall survival
rate at 5 years of approximately 90% for early-stage
(stage I and II) melanomas (Bajaj et al., 2020; Ger-
shenwald et al., 2017) and an overall survival rate at
3 years of around 55% for patients with unresectable
advanced melanoma (Wolchok et al., 2017). In addi-
tion to the stage-dependent severe drop in the dis-
ease-associated survival, recurrence of the disease
represents a major problem in melanoma, as more
than the 10% of patients diagnosed with stage I–II
melanoma have a relapse in the 5 years after the ini-
tial diagnosis (Bajaj et al., 2020; Lyth, 2018; von
Schuckmann et al., 2019). Despite all the efforts to
devise prevention and detection strategies, the inci-
dence of melanoma is expected to increase in the
forthcoming years (Whiteman et al., 2016) further
supporting the benefits to be gained by investing in
the development of predictive tools.
The prognosis of melanoma is currently assigned
almost entirely on the basis of a limited set of
histopathological markers (Kashani-Sabet, 2014;
Kashani-Sabet et al., 2017). In this context, tumor
thickness is the most important histopathological
characteristic included in the AJCC staging system
and it is officially considered as a prognostic factor
for melanoma progression in clinical practice (Foth
et al., 2016; Stiegel et al, 2018). However, due to the
clinical and biological heterogeneity of primary mela-
noma, survival can vary widely even among individu-
als considered to be within the same stage (Elmore
et al., 2018; Gershenwald et al., 2017), highlighting
the need for new prognostic tools to improve the
management of primary melanoma patients (Weiss
et al., 2015). Precision medicine focuses on classifying
early-stage melanoma patients on the basis of genetic
and other biochemical features in order to identify
profiles that are most likely to develop into more
advanced disease stages and to define more effective
treatments for the metastatic disease (Gogas et al.,
2009).
Serum is a highly accessible and valuable source of
biomarkers, containing tumor and host-related factors
that are correlated with tumor behavior and patient
prognosis (Palmer et al., 2011). Cytokines are key
mediators of the immune system with either pro-in-
flammatory or anti-inflammatory activity, and they
are serum factors with potential value as biomarkers.
In fact, cytokine profiling is providing valuable data
regarding patient classification in a wide range of dis-
eases, including cancer (D’Angelo et al., 2018; Johdi
et al., 2017; Obraztsov et al, 2019). In terms of tumor
activity, elevated Th2 cytokines [interleukin-4 (IL-4),
IL-5, and IL-13)] and decreased Th1 cytokines (IL-2
and IFN-c—interferon-c) suppress effective sponta-
neous antitumor immunity (Boyano et al., 1997; Boy-
ano et al., 2000; Nevala et al., 2009). In addition, the
IL-17A pro-inflammatory cytokine has been associ-
ated with poor prognosis in some tumors (Ma et al.,
2017) and elevated levels of mainly immunosuppres-
sive IL-10 and transforming growth factor beta
(TGF-b) have been also correlated to bad prognosis
(Lin et al., 2015; Zhao et al., 2015). Granulocyte–
macrophage colony-stimulating factor (GM-CSF) is a
hematopoietic growth factor that fulfills a fundamen-
tal role in macrophage and granulocyte differentia-
tion. While classically linked to antitumor activities
(Bhattacharya et al., 2015), there is growing evidence
that GM-CSF can also promote tumor progression
(Reggiani et al., 2017; Singel and Segal, 2016; Wang
et al., 2017a), supporting its inclusion in biomarker
studies.
In a previous study carried out on a large group of
melanoma patients and based on serum proteomic
analysis and immunoassays, we established prognostic
value of serum dermcidin (DCD) for stage II mela-
noma patients (Ortega-Martınez et al., 2016). DCD is
considered to play an important role in the cutaneous
microenvironment due to its antimicrobial activity
(Zeth and Sancho-Vaello, 2017). Nevertheless, DCD is
not just an antimicrobial peptide as it can stimulate
keratinocytes to produce cytokines through G protein
and mitogen-activated protein kinase activation (Paul-
mann et al., 2012). These data suggest a possible rela-
tionship between in situ and systemic immune
responses.
Accordingly, the purpose of this study was to
develop a tool with clinical applications to improve
the prognostic prediction of patients diagnosed with
early-stage (stage I–II) melanoma. To achieve this, we
adopted a machine learning approach that incorpo-
rated the serum measurements of GM-CSF, IFN-c,
TGF-b1, IL-4, IL-6, IL-10, IL-17A, and DCD, in con-
junction with clinical–pathological features of such
melanoma patients to determine the prognostic value
of these parameters.
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2. Materials and methods
2.1. Patients
Melanoma patients were recruited at the Dermatology
Units at the Basurto and Cruces University Hospitals
between 1990 and 2016. Inclusion criteria were as fol-
lows: (a) a histologically confirmed diagnosis of
malignant melanoma; (b) no treatment except pri-
mary surgery (including wide local excision); and (c)
no infection as judged by clinical evaluation and
absence of increased infectious parameters in the
blood.
Biopsies of suspicious lesions were analyzed by a
melanoma pathologist. Those patients with a positive
result for melanoma underwent a second surgery for
a wide local excision. Patients diagnosed with stage
III or IV melanoma were referred to the Oncology
Unit, while stage I or II patients (from now on
‘early-stage melanomas’) remained under the supervi-
sion of the Dermatology Unit. Upon removal of the
primary tumor, clinical checkups of patients with
early-stage melanomas were scheduled every 3 months
for the first 2 years of the follow-up and every
6 months thereafter, until a 5-year follow-up had
been completed. Annual revisions were then sched-
uled up to the 10th year postsurgery. The patients
who developed metastasis during the follow-up period
were again examined every 3 months for 2 years after
metastasis had been diagnosed. The presence or
absence of metastasis was assessed in all patients by
physical examination, as well as through laboratory
and radiological testing (X-rays and/or computed
tomography scanning). Some patients underwent sen-
tinel lymph node biopsy although it was not a gener-
alized procedure.
Disease stages were classified according to the AJCC
8th edition (Gershenwald et al., 2017). The clinical and
diagnostic data for each patient were collected retro-
spectively from centralized electronic and/or paper
medical records. For the statistical prediction analysis,
only melanoma patients at early disease stages (I and
II) were included; those patients that did not develop
metastasis within 2 years of follow-up were included in
the group named as ‘disease-free’.
The study was conducted in accordance with the
Declaration of Helsinki principles. It was approved by
the Euskadi Ethics Committee (reference 16-99), and
written informed consent was obtained from all the
subjects. The serum samples collected were stored at
80 °C at the Basque Biobank until use (https://
www.biobancovasco.org/).
2.2. Serum samples
Venous blood samples were drawn 1 month after sur-
gical excision of the lesions, and these samples were
used to obtain serum following the protocol estab-
lished at the Basque Biobank for Research. Briefly,
blood samples were allowed to clot at room tempera-
ture for at least 30 min and then centrifuged at 1000 g
for 10 min. The serum was collected and subsequently
divided into 500 µL aliquots; aliquots were stored at
80 °C until use.
2.3. Quantification of Granulocyte–Macrophage
Colony-Stimulating Factor (GM-CSF), Interferon-c
(IFN-c), Transforming Growth Factor beta (TGF-
b1), and Interleukins (IL) 4, 6, 10, and 17A in
serum
Upon reception from the Basque Biobank, serum sam-
ples were divided into 25 lL aliquots to avoid multiple
freeze/thaw cycles, and GM-CSF, IFN-c, IL-4, IL-6,
IL-10, IL-17A, and TGF-b1 were measured using mag-
netic bead-based multiple immunoassays (MILLI-
PLEX MAP Kit, Human High Sensitivity T Cell
Magnetic Bead Panel; EMD Millipore Corporation,
Darmstadt, Germany). Each assay included two cali-
bration curves for each of the proteins to be measured
(calibration ranges: GM-CSF, 1.22–5000 pgmL1;
IFN-c, 0.61–2500 pgmL1; IL-4, 1.83–7500 pgmL1;
IL-6, 0.18–750 pgmL1; IL-10, 1.46–6000 pgmL1;
IL-17A, 0.73–3000 pgmL1; and TGF-b1, 9.8–
10 000 ngmL1), with eight calibration points in each
curve. Two low- and two high-quality controls were
also included in the assays. In the case of TGF-b1,
serum samples were treated with 1N HCl, diluting the
samples 1 : 4 and then adding 2 µL of 1.0 N HCl
before incubating the mixture for 1 h at room tempera-
ture. The samples were then further diluted 1 : 6 in
assay buffer to achieve a final dilution of 1 : 30. In the
assays, we followed the protocol established by the
manufacturer. The plates were read on a Luminex
100TM apparatus (Luminex Corporation, Austin, TX,
USA): 50 events per bead; 150 µL of sample (or
100 µL in the case of TGF-b1); gate settings from 8000
to 15 000; reported gain as default; and time out 100 s.
The serum concentration of each protein was calculated
through a 5-parameter logistic curve-fitting method
using the XPONENT software (Luminex Corporation).
2.4. DCD Quantification in serum
Serum DCD was measured with an ELISA Kit (Cus-
abio Biotech Co., Ltd, Houston, TX, USA) according
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to manufacturer instructions as previously described
(Ortega-Martınez et al., 2016).
The optical density was determined on a microplate
reader (Synergy HT; BioTek Instruments, Inc.,
Winooski, VT, USA) set to 450 and 540 nm. Readings
at 540 nm were subtracted from those obtained at
450 nm to correct for optical imperfections in the
plate, and the serum DCD levels were calculated using
the GEN5 software (2005; BioTek Instruments, Inc.)
with a 4-parameter logistic curve fitting.
2.5. Statistical analysis
Variables of interest clearly deviated from a normal
distribution as assessed both visually and by means of
a Shapiro–Wilk test. As a consequence, all descriptive
statistic was expressed as the median along with the
95% confidence interval (CI), computed by bootstrap
resampling in which 10 000 samples were extracted
with replacement for each variable from the original
data and calculating the 95% percentile interval. Inter-
group comparisons were carried out using the
Kruskal–Wallis test when more than two groups were
involved and a two-sided Mann–Whitney U test when
only two groups were compared. In the latter case, in
addition to the P-values, the effect sizes were reported,
measured through the absolute Cliff’s delta value
(Cliff, 1993), which estimates the difference between
the probability that a value from one of the groups is
higher than that value from the other group, and vice
versa. The P-values were corrected for multiple com-
parisons by controlling the false discovery rate (FDR)
using the Benjamini–Hochberg procedure (Benjamini
and Hochberg, 1995), and those whose significance
level was below the threshold of 0.05 were considered
significant. Likewise, further inspection of statistical
significance was addressed by means of the shift func-
tion (Wilcox, 2012) as implemented in the rogme R
package (Rousselet et al., 2017), where deciles are
compared using a Harrell–Davis estimator, levels of
confidence are computed by a bootstrap estimation,
and the type I error is controlled to remain around
0.05 across all the decile comparisons. Comparison
among observed and expected frequencies was carried
out by chi-square test, and Fisher’s exact test was
employed for pairwise comparison.
2.6. Machine learning analysis
A machine learning analysis was performed in order to
assess the power of the data to correctly classify the
prognosis of melanoma patients. In situ melanoma
patients show an extremely good prognosis, while
patients are classified at stage III or IV when metasta-
sis is detected. Therefore, we focused on patients diag-
nosed at stages I and II due to the clinical relevance of
early metastasis prediction, of which there were 323
subjects in our cohort. Among these patients, 244
remained disease-free and 84 developed metastasis dur-
ing the follow-up period. The predictive power of dif-
ferent biomarkers was inspected in three different
variable domains: The histological domain, represented
by the Breslow thickness; the serum domain, which
involved all the serum variables indicated above; and a
multimodal domain, a conjunction of the variables
from the two previous domains. Missing information
was imputed by removing instances containing
unknown components, which reduced the input data
to 211 disease-free and 56 metastatic samples, respec-
tively. Subsequently, a nested cross-validation was
employed to assess both the optimization and general-
ization of the model. In the outer loop, a 10-fold
cross-validation repeated five times with different ran-
domization seeds was performed to estimate the gener-
alization error of the model. In the inner loop, a
stratified 10-fold cross-validation was implemented for
model optimization, which involved an exhaustive grid
tuning of the inner hyperparameters of a pipeline
assembled by robust scaling of the data, random over-
sampling of the class minority, a feature selection
based on the weights importance order found by a
logistic ridge regression model, and the fitting of classi-
fier used. A scheme of this workflow is shown in
Fig. S1.
Classification scores were computed using a battery
of five classification algorithms: logistic regression
(LR) with a L2 regularization term; support vector
machine with a radial basis kernel; a decision tree
(DT); Gaussian naive Bayes classifier; and the K-near-
est neighbors vote algorithm. All the different hyper-
parameters of the mentioned classifiers and the level of
shrinkage and the number of features to select were
tuned by an exhaustive grid search within the inner
loop. Finally, for each classifier, the balanced accu-
racy, which calculates the raw accuracy of each sample
weighted by the inverse prevalence of its true class, the
precision, recall, and F1 score were reported. In addi-
tion, a receiver operating characteristic (ROC) curve
was computed, such that the area under this curve
(AUC) provides a measure to evaluate the classifier
quality. The classifier with the highest ROC area was
finally considered the most efficient one.
All the machine learning analysis was performed
using scikit-learn, a library for machine learning writ-
ten in python (Pedregosa et al., 2011), and Imbal-
anced-learn, a Python toolbox to ‘tackle the curse of
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imbalanced datasets in Machine Learning’ (Lemâıtre
et al., 2017).
2.7. Disease-free survival analysis
Once the best algorithm and subset of biomarkers to
reflect the evolution of metastasis had been found, we
used this combination to fit the entire stage I/II sub-
population, allowing us to compute the ROC curve.
Subsequently, the optimal cutoff point on this curve
was determined using the index of union method,
which corresponds to computing the value where the
sensitivity and specificity are the closest to the AUC,
and the absolute difference between the specificity and
sensitivity is minimal (Unal, 2017). This cutoff point
allows us to define a class partition criterion, which
separates subjects with a high probability of develop-
ing metastasis from those with a low probability, as
witnessed through a Kaplan–Meier estimator imple-




A total of 448 melanoma patients were recruited (187
male, 261 female), with a median age at diagnosis of
56 years (95% CI: 54.0–60.0: Table S1). Cutaneous
melanoma was most often diagnosed in patients’
trunks (158 patients), followed by the lower limb (121
patients). Staging was based on the AJCC system
(Gershenwald et al., 2017), and most patients were
diagnosed as stage I or II (224 and 99 patients, respec-
tively), while only 38 were considered to be at a stage
related to metastasis, stage III (30) or IV (8). However,
119 (27%) of the 448 patients recruited developed
metastasis, including those with spread disease at the
moment of diagnosis and those who suffered from dis-
ease recurrence during the follow-up. Lymph node and
distant metastases were the main subtypes detected.
Additional information regarding the entire cohort
(in situ and stage I–IV patients) has been included in
the Table S1.
Considering patients at AJCC stages I and II as
early-stage melanoma patients (323 patients: 318
patients with cutaneous melanoma and five with non-
cutaneous melanoma), sex, age, and tumor location
frequencies were similar to those obtained from the
whole group (Table S1). Mean follow-up for the early-
stage melanoma cohort was of 5.5 years with a median
of 3.9 years. Seventy-four of these early-stage
melanoma patients (22.9%) developed metastasis dur-
ing the first years of the follow-up. For those early-
stage patients that developed metastasis, the mean
interval from the removal of the primary tumor until
the diagnosis of a metastasis was 2.8 years with a med-
ian interval of 1.8 years. By contrast, 239 patients
remained disease-free (without recurrence or metasta-
sis); mean follow-up of these patients was 6.3 years
with a median of 4.5 years. The vast majority of
patients that developed metastasis (93.2%) showed a
Breslow thickness > 1 mm, and ulceration was more
frequently detected on those early-stage patients with
recurrent disease (35.1% vs 10.4%; v2 test P-
value < 0.001). Metastasis development was associated
with primary tumor localization (P < 0.05) although
we could not determine any localization with signifi-
cantly higher risk for metastasis development. Interest-
ingly enough, upper limb was revealed as a location
with better prognosis (pFDR < 0.01; Table 1).
3.2. Analysis of serum GM-CSF, IL-4, IL-6, IL-10,
IL-17A, IFN-c, TGF-b, and DCD
As previously mentioned, blood samples were collected
upon surgical excision of melanoma lesions. In a first
analysis including the entire cohort of recruited
patients (in situ and stage I–IV melanoma patients), the
amount of GM-CSF, IL4, IL-6, IL-10, IL-17A, and
TGF-b detected in serum was independent of the age
of the melanoma patients and it did not vary between
the sexes. However, there were significant differences
between the sexes in the levels of IFN-c and DCD (|
d| = 0.2, pFDR < 0.01 and |d| = 0.2, pFDR < 0.01,
respectively: data not shown). Of the proteins studied,
the median serum level in the melanoma patients at the
time of diagnosis was considered according to the stage
of the tumor. No significant differences were observed
in the median serum levels among patients of different
AJCC stages (including in situ and stages I–IV), nor
were any differences found between the distinct histo-
logical subtypes of melanoma (data not shown).
Focused on early-stage patients (stages I–II), none of
the cytokines or DCD revealed statistically significant
differences when comparing stage I vs stage II patients
(Table 2).
To analyze the prognostic value of these proteins,
we compared serum cytokine and DCD levels of early-
stage melanoma patients that remained disease-free at
the end of the follow-up period, with those obtained
from early-stage patients who developed metastasis.
Significant differences were observed in the serum IL-4
and IL-6 levels between these two groups of patients
and were associated with a moderate effect size (|
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d| = 0.30 pFDR < 0.01 and |d| = 0.20 pFDR = 0.04:
Table 2). At the time of diagnosis, the serum IL-4
levels of patients who developed metastasis doubled
those observed in patients who remained disease-free
(62.27 vs 31.96 pgmL1, respectively, P < 0.01). A
similar trend was detected regarding serum IL-6 (4.71
vs 3.29 pgmL1, P < 0.04). No significant differences
in serum GM-CSF, IL-10, IL-17A, IFN-c, TGF-b,
and DCD were observed.
3.3. Prognostic power of the melanoma markers
The performance of the different classifiers was assessed
for the subpopulation of subjects at AJCC stages I and II
(Table S2). In all the three domains, a LR classifier
exhibited the best performance through the ROC area,
and the most generalizable results were reflected by the
smallest gap between the training and test scores. The
Breslow thickness represents a biomarker of melanoma
metastasis that correctly classified 73% of the patients
and generating 83% of the ROC area (Fig. 1A).
Although the serum levels solely had a poorer prognostic
value, when combined with the Breslow thickness, they
significantly improved the cross-validated performance
of this biomarker, exceeding a balanced accuracy of 80%
(Wilcoxon signed-rank test, P < 0.01) and a ROC area
close to the 90% (Wilcoxon signed-rank test, P < 0.01).
Furthermore, these data clearly pointed to the cytokines
IL-4, GM-CSF, and DCD as the most powerful
biomarkers in predicting melanoma metastasis in con-
junction with the Breslow thickness. Indeed, these
parameters were selected at least the 80% of the times in
all the partitions after the feature selection process (see
panel B of Fig. 1). This subset of variables was followed
by the IL-10 being 66% of the times selected and the IL-
6, IL-17A, IFN-c, and TGF-b below the 50%. In sum,
cytokines and DCD alone represent a weak source of
melanoma prognosis. For instance, the subset composed
of GM-CSF, IL-4, and DCD submitted to the LR classi-
fier yields a 59.82% balanced accuracy, which is only
moderately better than predicting by random chance,
and a 66.97% ROC area. However, their importance
resides in the complementary role as to melanomametas-
tasis prediction when they are combined with a strong
predictive biomarker such as Breslow thickness.
Notably, the decile distribution for these potential
biomarkers exhibited a clear tendency to separate
between subjects in stages I and II who developed
metastasis and those who remained disease-free (panel
A in Fig. 2). Both the distribution of the serum IL-4
levels and the Breslow thickness were higher in the
metastatic subpopulation, whereas this tendency
switched toward lower levels of GM-CSF. Moreover,
when the differences in the distribution of these vari-
ables were addressed by means of the shift function,
their predictive power was clearly evident, especially
that of the Breslow thickness where the separation of
the melanoma outcome was significant across its whole
spectrum. This was followed by that of IL-4, which
began to display a significant separation around the
median, whereas GM-CSF started to discriminate
these subpopulations above its 8th decile (panel B in
Fig. 2). For DCD, nevertheless, this class-separating
Table 1. Clinicopathological characteristics of stage I-II patient
cohort. ALM, acral lentiginous melanoma; LM, lentigo maligna;
LMM, lentigo maligna melanoma; m/f, males/females; NM, nodular
melanoma; SSM, superficial spreading melanoma.
Characteristics
Total Disease-free Metastasis
n (m/f) n (m/f) n (m/f)
Stage
I 224 (94/130) 204 (87/117) 20 (7/13)
II 99 (40/59) 45 (17/28) 54 (23/31)
n (%) n (%) n (%)
Tumor locationa
Head/neck 46 (14.5) 33 (13.5) 13 (17.8)
Trunk 125 (39.3) 101 (41.2) 24 (32.9)
Upper limb 32 (10.1) 32 (13.1) 0 (0)
Lower limb 86 (27.0) 64 (26.1) 22 (30.1)
Hand/foot 24 (7.5) 12 (4.9) 12 (16.4)
Others 5 (1.6) 3 (1.2) 2 (2.7)
nd 5 4 1
Melanoma subtypes
SSM 170 (61.2) 151 (67.4) 19 (35.2)
NM 58 (20.9) 38 (17.0) 20 (37.0)
LMM 18 (6.5) 17 (7.6) 1 (1.9)
LM 0 (0) 0 (0) 0 (0)
ALM 17 (6.1) 8 (3.6) 9 (16.7)
Others 15 (5.4) 10 (4.5) 5 (9.3)
nd 45 25 20
Breslow thickness (mm)
≤ 1.0 159 (52.1) 155 (63.0) 4 (6.8)
> 1.0–2.0 71 (23.3) 53 (21.5) 18 (30.5)
> 2.0–4.0 45 (14.8) 27 (11.0) 18 (30.5)
> 4.0 30 (9.8) 11 (4.5) 19 (32.2)
nd 18 3 15
Ulcerationb
Yes 52 (16.1) 26 (10.4) 26 (35.1)
No 271 (83.9) 223 (89.6) 48 (64.9)
Sentinel lymph node
Not conducted 68 (36.6) 54 (36.7) 14 (35.9)
Negative 116 (62.4) 93 (63.3) 23 (59.0)
Positive 2 (1.0) 0 (0) 2 (5.1)
nd 137 102 35
a
Metastasis development was associated with primary tumor local-
ization (v2 test P-value < 0.05).
b
Ulceration was more often observed on early-stage patients that
developed metastasis (v2 test P-value < 0.001).
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tendency is not as evident (Fig. S2), which may denote
a synergetic role emerging beyond the univariate sce-
nario. This also seems to be the same for the rest of
variables of interest (Fig. S2).
More importantly, these findings can be easily incor-
porated into clinical protocols by providing a general
optimum cutoff from the data from which a prediction
of metastasis can be performed. Using the same sub-
population of subjects (I/II melanoma patients), we fit-
ted the entire data using the best classifier and the
subset of features found previously (i.e., a LR classifier
with the features Breslow thickness, GM-CSF, IL-4,
and DCD), and we computed the optimal point
on the ROC curve that corresponded in this case to
FPR (1-specificity) = 0.11 and TPR (sensitivity) = 0.79
(see panel A, Fig. 3). This point defines a critical
threshold that allows us to separate subjects in terms
of their prognosis, which for our classifier can be easily














This equation therefore defines a hyperplane in our
feature space such that any subject lying above it is
Table 2. Comparison of serum cytokine and DCD levels between AJCC stage I and II patients who were disease-free or developed
metastasis during follow-up. Median values of serum analysis. Serum levels of GM-CSF, IL-4, IL-6, IL-10, IL-17A, and IFN-c are expressed in
pgmL1. TGF-b levels are expressed in ngmL1 and DCD in µgmL1. Square brackets reflect the lower and upper 95% confidence




|d|, pFDRI II Disease-free Metastasis
GM-CSF 122.56 [107.17–140.39] 137.86 [104.20–170.74] < 0.01, 0.96 121.39 [103.17–138.63] 131.55 [101.01–153.24] 0.03, 0.72
IL-4 35.95 [28.88–41.50] 37.81 [28.42–56.31] 0.10, 0.44 31.96 [27.76–38.06] 62.27 [39.06–92.21] 0.30, < 0.01
IL-6 3.30 [2.91–3.98] 4.27 [3.23–5.46] 0.14, 0.44 3.29 [2.82–3.87] 4.71 [3.3–5.9] 0.20, 0.04
IL-10 10.23 [7.95–13.76] 11.34 [7.38–16.35] 0.06, 0.73 11.23 [7.89–14.83] 10.03 [7.78–15.31] 0.05, 0.67
IL-17A 19.35 [17.12–22.24] 16.51 [12.85–22.07] 0.04, 0.79 17.88 [16.33–20.06] 20.09 [14.89–24.33] 0.04, 0.67
IFN-c 17.95 [15.92–20.04] 19.07 [13.94–24.57] 0.01, 0.96 17.23 [14.84–19.34] 22.40 [16.99–26.91] 0.12, 0.37
TGF-b 49.18 [45.30–54.21] 46.67 [40.13–55.30] 0.11, 0.44 49.71 [45.32–53.68] 48.18 [40.13–60.44] 0.04, 0.67
DCD 4.81 [4.31–5.01] 4.43 [3.98–4.88] 0.06, 0.73 4.78 [4.39–5.01] 4.38 [3.92–4.84] 0.07, 0.67
a
The American Joint Committee of Cancer (AJCC) staging system for melanomas was used.
Bold values highlight cytokines (IL-4 and IL-6) with significant differences among early-stage melanoma patients that developt metastasis
and those that remained metastasis-free during the follow-up.
Fig. 1. LR analysis. (A) Classification of the three variable domains considered: Breslow thickness, cytokines, and DCD serum variables. (B)
In the scenario combining histological and serum variables, their participation across the folds is provided by the feature selection step in
the inner cross-validation loop. Black colors in each column denote the predictors that were included in the final LR model in each of these
folds. Data are from the early-stage melanoma cohort (n = 323).
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classified as metastatic and those below it are consid-
ered disease-free. Furthermore, subjects stratified with
respect to this critical threshold could be differentiated
by their probability of eventually developing metastasis
during the follow-up period (Kaplan–Meier log-rank
test P < 0.001, as shown in panel B of Fig. 3).
Remarkably, we found a prognostic plane involving
the serum levels of IL-4, GM-CSF, and DCD in con-
junction with the Breslow thickness that could accu-
rately classify subjects according to their melanoma
outcome. This equation could be easily translated to a
clinical setting, and inspecting the signs of the coeffi-
cients in this equation, we can clearly see that an
increase in IL-4 and the Breslow thickness tend to shift
subjects above this plane, indicating a worse prognosis,
whereas GM-CSF and DCD levels act in the opposite
direction.
Finally, in order to account for the effect of addi-
tional prognostic factors in the present findings, we
repeated the previous analyses considering also age,
sex, and ulceration as predictive variables in the full
feature matrix used to train the LR. Their inclusion
yields an increase in the balanced accuracy rate
(81.85%), precision (60.55%), and recall (78.60%) and
a slight decrease in the ROC area (88.80%). Such
changes are primarily mediated by the role of gender
as an important predicting factor due to the number
of times it is selected during the feature selection pro-
cess. Yet, it still is preceded by Breslow, IL-4, GM-
CSF, and DCD variables. In contrast, both age and
ulceration, respectively, contribute fewer times to
forming the predictive model (Fig. S3). Subsequently,
a Bayesian approach shows that a model incorporating
age, gender, and ulceration in addition to the variables
of the rule provided by the prognostic equation (1)
adds such amount of complexity to the model that
leads to an increase in the Bayes information criterion
(BIC) from 334.39 to 355.54, providing a very strong
evidence against their inclusion (Bayes Factor > 150)
(Wagenmakers, 2007). Likewise, in spite of the afore-
mentioned predictive importance of gender, its sole
inclusion is also strongly disfavored (BIC = 349.07).
Fig. 2. (A) Decile distribution of metastatic and disease-free subjects for the Breslow thickness, GM-CSF, and IL-4. (B) For this subset of
features, the shift function displays the difference between the deciles in both subgroups of subjects. Positive values of the shift function
are in blue, corresponding to larger decile values in the disease-free group than in the metastatic group, while red values illustrate the
opposite scenario.
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4. Discussion
An accurate diagnosis is an essential first step in can-
cer management. Most melanoma cases are detected at
early disease stages, and when possible, excision biopsy
is the selected procedure to treat suspicious melanocy-
tic lesions. According to the AJCC 8th classification,
Breslow thickness, together with the ulceration, is
important variable that should be considered in tumor
staging (https://cancerstaging.org/). In addition, several
histological biomarkers (e.g., Melan-A, Pmel) are rou-
tinely employed for diagnostic purposes (Mohammad-
pour et al., 2019). In this regard, important efforts are
being made in order to achieve less invasive techniques
or to improve the accuracy of diagnostic markers
(Svedman et al., 2016). Indeed, early and precise prog-
nostic markers are urgently needed for melanoma due
to its strong metastatic capacity and, particularly,
given the low survival rate of metastatic patients (5-
year overall survival probability of 23.4–32% for stage
IIID patients; Bajaj et al., 2020; Gershenwald et al.,
2017). Moreover, risk of recurrence for early-stage
(stage I–II) melanomas must also be considered with
5-year probability values ranging from 8.8% to 74.5%
depending on the substage (Bajaj et al., 2020). Accord-
ing to Rutkowski and Lugowska (2014), highest recur-
rence rate is observed within 2–3 years after surgical
treatment while recurrence probability decreases to
< 5% in patients with treated stage I–III melanomas
and 5 years of disease-free follow-up. In a cohort simi-
lar to ours, median time until recurrence was set at
1.7 years although with clear differences among
tumors with different Breslow thickness (Lyth, 2018).
Our data, with a median time of 1.8 years, corroborate
published data. According to these figures, intense
medical monitoring should be implemented in the first
2–3 years after treatment, even for early-stage cases,
representing an important medical and economic bur-
den. Therefore, it would be useful if early patients
could be rapidly classified into high or low recurrence
risk groups when contemplating efficient and sustain-
able personalized follow-up programs. In this sense, to
assuage the unpredictable clinical behavior of mela-
noma, much research has focused on the discovery of
prognostic factors to improve the prognostic accuracy
for this type of skin cancer (Kashani-Sabet, et al.,
2017). In this regard, our study focused on the discov-
ery of prognostic biomarkers capable of evaluating the
metastatic risk of patients identified at early stages of
the disease (stages I–II). Moreover, we defined a clini-
cally applicable mathematical tool to accurately clas-
sify such melanoma patients. Ideally, analyzed factor
should have been able to accurately predict metastatic
risk of all stage I and II substages as it is well known
that despite being considered early stages, differences
are on the recurrence-free survival probabilities of dif-
ferent substages (Bajaj et al., 2020; Gershenwald et al.,
2017; von Schuckmann et al., 2019). Nevertheless, our
cohort size did not allow such stratification. In addi-
tion, it is described that melanoma-specific survival
rate describes a continuous decrease over time even for
stage I melanoma patients, classically linked to very
good prognosis (Lo et al., 2018). In fact, among stage
I patients that die due to melanoma, only 29% of
deaths occur during the first 5 years after diagnosis.
Therefore, with a median follow-up period of
4.5 years, we may have not been able to detect late
recurrences although it represents a powerful tool to
correctly classify the major part of early-stage patients
with high risk for metastasis development.
Fig. 3. (A) ROC curve from the whole-stage I/II dataset. The optimal cutoff point on this curve defines a plane that maximally separates
metastatic and disease-free progression. The best subset of biomarkers corresponds to Breslow thickness, IL-4, GM-CSF, and DCD. (B)
Kaplan–Meier analysis. The cutoff plane provides a condition to significantly separate subjects with a worse prognosis from those with a
better prognosis.
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Currently, predicting patient outcome mainly relies
on staging based on the histopathological parameters
described previously, while treatment options are often
based on the BRAF mutation (Karagiannis et al.,
2015). Nevertheless, patient monitoring, especially
upon surgical removal of the primary tumor, requires
other variables to be analyzed. As a systemic system
for information transfer, serum represents a complex
but accessible sensor. To date, LDH has been one and
perhaps the only clinical serological biomarker for
melanoma, with increasing values interpreted as dis-
ease progression. However, an increase in serum LDH
levels may also occur in other settings, which means
employing some caution before reaching any conclu-
sion (Karagiannis et al., 2015).
Serological cytokines reflect the general immunologi-
cal state of the body, offering information regarding
the cytokines released by tumors and those that accu-
mulate in the tumor microenvironment (Wang et al.,
2017b). The melanoma microenvironment contains
stromal cells and immune cells like T or B lympho-
cytes, NK cells, or tumor-associated macrophages
(Jiang et al., 2019; Terren et al., 2019). Most of these
cells secrete cytokines that may play a key role in
inhibiting or promoting tumor progression (Jiang
et al., 2019). The pro-inflammatory cytokines IL-4 and
IL-6, produced either by host immune cells or by
tumor cells themselves, are associated with tumor
malignancy in patients and animal cancer models (Ito
et al., 2017; Setrerrahmane and Xu, 2017; Surcel et al.,
2017). At the cutaneous level, keratinocytes secrete IL-
6 in order to enhance T-cell-mediated antitumor activ-
ity, and therefore, high IL-6 levels are considered a
marker for immune system upregulation (Setrerrah-
mane and Xu, 2017; Surcel et al., 2017). IL-4 is the
most important Th2 cytokine, and it is mainly pro-
duced by activated T cells, mast cells, basophils, and
eosinophils in order to regulate lymphocyte prolifera-
tion and survival (Setrerrahmane and Xu, 2017). Inter-
estingly, elevated serum IL-6 was correlated with a
poor prognosis in melanoma, while IL-4 is thought to
promote the proliferation and survival of several can-
cer cells (Gocheva et al., 2010; Jobe et al., 2018; Yu
et al., 2019). In line with previous findings, early-stage
(I or II) melanoma patients that developed metastasis
had significantly higher levels of serum IL-4 and IL-6
than patients who did not develop metastasis during
the follow-up.
Our previous attempt to identify novel serological
prognostic markers identified a threshold for serologi-
cal DCD that was associated with a poor prognosis
value for melanoma patients diagnosed specifically at
AJCC stage II (Ortega-Martınez et al., 2016).
Consistent with this finding, DCD, a major human
antimicrobial peptide in human skin (Paulmann et al.,
2012; Zeth and Sancho-Vaello, 2017), was also recently
proposed as a serological marker for the diagnosis and
staging of hepatocellular carcinoma (Qiu et al., 2018).
The current study including a new cohort of mela-
noma patients revealed that DCD is a marker of meta-
static progression, although other serological
parameters appear to have greater predictive potential
than DCD, such as IL-4 and GM-CSF. These differ-
ences with our previous study (Ortega-Martınez et al.,
2016) may be due to the patient stratification, as both
stage I and stage II melanoma patients were included
in separate groups for the DT analysis.
It is well described that serum components may vary
before, during, and after tumor excision surgery
(Grimm et al., 2016; Kahn et al., 2015) which supports
the need for a standardized protocol for blood collec-
tion. In this study, blood was drawn with a controlled
protocol, always 1 month after tumor excision. The
fact that blood was withdrawn after surgery may have
diminished the detection of tumor-related cytokines;
nevertheless, it represents an excellent sensor for the
detection of melanoma-related effects even when
tumor mass remains undetectable.
The Breslow thickness is a crucial prognostic factor,
with substantial evidence confirming a direct relation-
ship between Breslow thickness and survival (Stiegel
et al., 2018). Accordingly, we show that Breslow thick-
ness is the most important risk factor for the malig-
nant progression of melanoma as this variable
achieved highest predictive scores in our analysis.
Nonetheless, a significant increase in the predictive
power of Breslow thickness was achieved by combin-
ing it with data regarding serum IL-4, GM-CSF, and
DCD, resulting in the development of an algorithm to
identify early-stage melanoma patients with a high risk
of developing metastasis during the follow-up. Accord-
ing to this algorithm, a high Breslow thickness and
serum IL-4 levels in early-stage melanoma patients are
associated with a poor prognosis, whereas GM-CSF
and DCD levels decrease in patients in whom the dis-
ease outcome is poor. These results are consistent with
other studies describing an antitumor effect of GM-
CSF and DCD (Hong, 2016; Ortega-Martınez et al.,
2016). Our data also revealed the importance of IL-10
and IL-6 in predicting metastatic progression, albeit
they provide a subleading and fluctuating contribution
to melanoma outcome prediction compared to Breslow
thickness and serum levels of IL-4, GM-CSF, and
DCD.
The presence of ulceration is another important fac-
tor that has been usually associated with a lower
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survival rate (Gershenwald et al., 2017). It also
increases the aggressiveness of melanomas and leads
thin tumors to exhibit comparable survival rates to
those nonulcerated at later stages (Hawkins et al.,
2019). Interestingly, our data display a significantly
greater proportion of metastatic cases in patients with
ulcerated tumors compared to those cases lacking of
ulceration. However, this is not translated into an
improvement in the classification rates for melanoma
outcome when combined with the rest of the biomark-
ers considered in this study. Since both ulceration and
Breslow thickness show a significantly large correlation
(Point-Biserial r = 0.51, P-value < 0.001), very little to
null information is gained when both variables are
combined in the same predictive model.
According to the 8th edition of the AJCC (Gershen-
wald et al., 2017), SLNB should be routinely applied
as a staging procedure for patients with T1b-T4. As
shown by von Schuckmann et al. (2019), SLNB pro-
vides a more accurate classification of patients and a
consequent increase rate of disease-free survival for I–
II stage patients. Nevertheless, our results, although
limited, are independent of whether SLNB was applied
or not. Indeed, similar disease-free vs metastasis ratios
were observed on those individuals recruited prior to
the implantation of the SLNB procedure compared
with those subjected to SLNB. Of mention, we
obtained SLNB-related information only for the 57%
of all stage I-II patients as this procedure was not
standardized for the entire period of patient recruit-
ment. As a consequence, the insertion of such variable
in the predictive model would substantially reduce the
size of the dataset, whereby increasing the risk of over-
fitting. Furthermore, and in agreement with patient
classification in stages I–II, the results of those who
underwent SLNB were negative, so no information
gain across individuals would be achieved by its inclu-
sion in this particular scenario. Nonetheless, we con-
sider that incorporation of the information regarding
SLNB would be definitely relevant when dealing with
patients across all melanoma stages. Future studies
incorporating SLNB detection in the patients’ clinical
routine will attempt to explore the influence of this
variable in the present findings.
In summary, the use of machine learning techniques
has helped to define an algorithm capable of accu-
rately classifying early-stage melanoma patients with a
high or low risk of developing metastasis. The equa-
tion generated took into account the serum IL-4, GM-
CSF, and DCD levels and the Breslow index, and it
could stratify melanoma patients to be triaged at the
time of diagnosis and initial surgery, or it could also
be used clinically to determine whether stage I or II
melanoma patients should receive adjuvant therapy to
prevent metastatic progression. In addition, our find-
ings are valid regardless of the melanoma location and
histology. Future studies will attempt to validate cur-
rent data and specify the predictive rules in more strat-
ified scenarios, for which the recruitment of larger
populations of patients than in the current study will
be required to overcome the chance of data overfitting.
5. Conclusions
We have developed a prognostic equation that considers
the serum IL-4, GM-CSF, and DCD levels, along with
the Breslow thickness to accurately classify melanoma
outcome in early-stage (I-II) patients. In this sense, a rig-
orous follow-up is recommended for early-stage mela-
noma patients with a high Breslow thickness, high serum
IL-4 levels, and lowGM-CSF andDCD levels at the time
of diagnosis, given the elevated risk for these patients to
developmetastasis during follow-up.
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